Skip to main content
. 2021 Apr 8;23(4):429–438. doi: 10.1016/j.neo.2021.03.005

Fig. 1.

Fig. 1

Analysis of Akt1, Akt2, AMPKα1, and AMPKα2 expression in TNBC lymph node and lung metastases. (A) IHC scoring of Akt1, Akt2, AMPKα1, and AMPKα2 cytoplasmic expression in TNBC lymph node metastases. Samples were scored on scales of 0-3 for both intensity and distribution percentage, and the values were added together (n = 45). (B) Subcellular localization of Akt1, Akt2, AMPKα1, and AMPKα2 in TNBC lymph node metastases (n = 45). (C) IHC scoring of Akt1 and Akt2 cytoplasmic expression in TNBC lung metastases. Samples were scored on scales of 0-3 for both intensity and distribution percentage, and the values were added together (n = 6). (D) Subcellular localization of Akt1 and Akt2 in TNBC lung metastases (n = 6). IHC, Immunohistochemistry; TNBC, triple negative breast cancer.